Karyopharm Ebitda vs Income Tax Expense Analysis
| KPTI Stock | USD 0.67 0 0.51% |
Karyopharm Therapeutics financial indicator trend analysis is infinitely more than just investigating Karyopharm Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Karyopharm Therapeutics is a good investment. Please check the relationship between Karyopharm Therapeutics Ebitda and its Income Tax Expense accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.
Ebitda vs Income Tax Expense
Ebitda vs Income Tax Expense Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Karyopharm Therapeutics Ebitda account and Income Tax Expense. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Karyopharm Therapeutics' Ebitda and Income Tax Expense is -0.17. Overlapping area represents the amount of variation of Ebitda that can explain the historical movement of Income Tax Expense in the same time period over historical financial statements of Karyopharm Therapeutics, assuming nothing else is changed. The correlation between historical values of Karyopharm Therapeutics' Ebitda and Income Tax Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebitda of Karyopharm Therapeutics are associated (or correlated) with its Income Tax Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Tax Expense has no effect on the direction of Ebitda i.e., Karyopharm Therapeutics' Ebitda and Income Tax Expense go up and down completely randomly.
Correlation Coefficient | -0.17 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Ebitda
Income Tax Expense
Most indicators from Karyopharm Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Karyopharm Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.The Karyopharm Therapeutics' current Enterprise Value is estimated to increase to about 1.1 B, while Selling General Administrative is projected to decrease to under 67.5 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 206.4M | 151.9M | 141.1M | 148.1M | Total Revenue | 209.8M | 157.1M | 146.0M | 153.3M |
Karyopharm Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Karyopharm Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Karyopharm Therapeutics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 295.0M | 313.1M | 305.3M | 358.2M | 240.4M | 238.3M | |
| Other Current Liab | 41.4M | (6.4M) | 67.5M | 57.4M | 59.7M | 62.7M | |
| Total Current Liabilities | 46.4M | 297K | 73.7M | 65.9M | 69.5M | 73.0M | |
| Total Stockholder Equity | 49.8M | 50.5M | (79.7M) | (16.7M) | (136.2M) | (129.4M) | |
| Property Plant And Equipment Net | 3.0M | 2.2M | 1.6M | 7.4M | 4.9M | 3.0M | |
| Current Deferred Revenue | 2.3M | 297K | 69.1M | 25.1M | 28.8M | 15.7M | |
| Net Debt | (19.0M) | 32.0M | (21.2M) | 37.8M | 124.8M | 131.0M | |
| Retained Earnings | (873.3M) | (1.1B) | (1.2B) | (1.3B) | (1.5B) | (1.4B) | |
| Accounts Payable | 985K | 4.5M | 1.6M | 2.8M | 3.1M | 3.5M | |
| Cash | 128.9M | 85.9M | 190.5M | 135.2M | 52.2M | 101.6M | |
| Non Current Assets Total | 21.3M | 23.5M | 47.2M | 31.4M | 6.5M | 6.2M | |
| Non Currrent Assets Other | 16.2M | (2.9M) | 44.9M | 23.4M | 1.6M | 1.6M | |
| Other Assets | 714K | 34.3M | 45.6M | 633K | 1.0 | 0.95 | |
| Cash And Short Term Investments | 264.0M | 273.5M | 228.6M | 278.0M | 191.4M | 201.7M | |
| Common Stock Shares Outstanding | 62.0M | 72.0M | 75.2M | 81.9M | 114.2M | 119.9M | |
| Liabilities And Stockholders Equity | 295.0M | 313.1M | 305.3M | 358.2M | 240.4M | 238.3M | |
| Non Current Liabilities Total | 245.2M | 262.2M | 385.0M | 374.8M | 307.2M | 322.5M | |
| Other Current Assets | 1.5M | 559K | 20.4M | 20.9M | 12.5M | 13.1M | |
| Other Stockholder Equity | 923.1M | 1.1B | 1.1B | 1.3B | 1.4B | 748.9M | |
| Total Liab | 245.2M | 262.5M | 385.0M | 374.8M | 376.6M | 395.5M | |
| Property Plant And Equipment Gross | 13.7M | 11.6M | 1.6M | 1.1M | 11.4M | 12.0M | |
| Total Current Assets | 273.7M | 289.5M | 258.1M | 326.8M | 233.9M | 215.6M | |
| Accumulated Other Comprehensive Income | (37K) | 518K | 191K | (638K) | (161K) | (169.1K) | |
| Short Term Debt | 1.6M | 1.9M | 4.6M | 5.7M | 6.6M | 8.5M | |
| Property Plant Equipment | 3.0M | 2.2M | 1.6M | 1.1M | 1.3M | 2.2M | |
| Net Tangible Assets | 49.8M | 50.5M | (79.7M) | (16.7M) | (15.0M) | (14.2M) | |
| Long Term Debt | 109.9M | 117.9M | 169.3M | 170.1M | 170.9M | 179.5M | |
| Retained Earnings Total Equity | (873.3M) | (1.1B) | (1.2B) | (1.3B) | (1.2B) | (1.1B) | |
| Short Term Investments | 133.1M | 163.3M | 38.2M | 142.8M | 139.2M | 115.6M | |
| Capital Surpluse | 923.1M | 1.1B | 1.1B | 1.3B | 1.5B | 824.8M | |
| Other Liab | 8.5M | 75.8M | 144.6M | 215.7M | 248.0M | 260.4M | |
| Net Invested Capital | 159.6M | 168.5M | 169.3M | 170.1M | 34.7M | 33.0M | |
| Net Working Capital | 232.2M | 216.3M | 201.9M | 284.3M | 164.4M | 233.5M | |
| Short Long Term Debt Total | 111.5M | 119.8M | 169.3M | 173.0M | 177.0M | 162.5M |
Currently Active Assets on Macroaxis
When determining whether Karyopharm Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Karyopharm Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Karyopharm Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Karyopharm Therapeutics Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share 1.247 | Quarterly Revenue Growth 0.077 | Return On Assets (0.34) | Return On Equity (8.91) |
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.